BofA analyst Tazeen Ahmad raised the firm’s price target on Rhythm Pharmaceuticals (RYTM) to $128 from $122 and keeps a Buy rating on the shares. The firm adjusted targets among its small-to-mid cap biotech coverage as part of a Q3 earnings preview for the group.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RYTM:
- Rhythm Pharmaceuticals price target lowered to $139 from $157 at Goldman Sachs
- Rhythm Pharmaceuticals price target raised to $129 from $122 at Morgan Stanley
- Buy Rating for Rhythm Pharmaceuticals: Promising Setmelanotide Efficacy and Market Potential in Hypothalamic Obesity
- Rhythm Pharmaceuticals price target raised to $110 from $100 at H.C. Wainwright
- Rhythm Pharmaceuticals price target raised to $142 from $135 at Citizens JMP